|
| CASE REPORT |
 |
|
|
| Year : 2020 |
Volume
: 31 | Issue : 2 | Page
: 521-523 |
|
Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonide
Umesh Lingaraj1, Kishan Aralapuram1, Sreedhara Chikkanayakanhalli1, Akila Vishwanathan1, Mahesha Vankalakunti2
1 Department of Nephrology, Institute of Nephro-urology, Bengaluru, Karnataka, India
2 Department of Nephropathology, Manipal Hospitals, Bengaluru, Karnataka, India
Correspondence Address:
Umesh Lingaraj
Department of Nephrology, Institute of Nephro-urology, Victoria Hospital Campus, Bengaluru - 560 002, Karnataka
India
  | Check |
DOI: 10.4103/1319-2442.284029 PMID: 32394927 
|
|
|
Recurrence of glomerulonephritis is the third-leading cause of allograft loss. Graft loss due to IgA nephropathy occurs in 10% at 10-year follow-up. The NEFIGAN trial demonstrated that Target Release Formulation (TRF) of budesonide is a specific treatment for IgA nephropathy targeting intestinal mucosal immunity upstream of disease manifestation with favorable safety profile. We are reporting a case of successful treatment of a patient with posttransplant IgA nephropathy with TRF of budesonide.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
|
|
